Working With CROs

Partner with our owned clinical sites, specialist populations, Clinical Pharmacology Units, and Human Challenge Unit to deliver fast, predictable early‑phase studies. Designed for CROs seeking reliable timelines and expanded capabilities  

Schedule a Call
Project teams

We help CROs deliver faster, more predictable, and higher‑quality early‑phase studies. With owned clinical sites, specialist populations, Clinical Pharmacology Units, and a dedicated Human Challenge Unit, we expand your capabilities while protecting your client relationships.  

Speak with our team

Working with CRO's 

We help CROs deliver faster, more predictable, and higher‑quality early‑phase studies. With owned clinical sites, specialist populations, Clinical Pharmacology Units, and a dedicated Human Challenge Unit, we expand your capabilities while protecting your client relationships.  

 

 

 


 

 

Experience

With decades of operational delivery across first‑in-human programs, early clinical development, and infectious disease challenge studies, our teams bring practical, hands‑on expertise to CRO partnerships.

Expertise

Our physicians, project managers, and scientists have extensive experience in Phase I–III studies, PK/PD modelling, specialist participant populations, and viral challenge trial design and delivery.

Quality

We operate regulated, accredited units including Clinical Pharmacology Units and our Human Challenge Unit. All studies are conducted using validated processes, audited quality systems, and transparent delivery frameworks.


CRO Services

Owned Clinical Sites For Predictable Recruitment

  • Guaranteed bed capacity

  • Accurate timeline forecasting

  • Faster site readiness

    No dependency on third‑party availability

Specialist Populations for Complex Studies

 

  • Renally impaired volunteers

  • Hepatically impaired volunteers

  • Pharmacogenetic populations

  • Targeted early‑phase cohorts

Phase I Clinical Pharmacology Units & Study types

  • FIH 

  • SAD/MAD – PoC  

  • PK/PD 

  • Drug–drug interactions 

  • BA/BE

  • Pharmacogenetics  

  • Biosimilars  

Human Challenge Unit for Infectious Disease Studies

  • GMP challenge agent manufacturing 

  • In‑house virology, Immunology, Molecular and Bacterial laboratory 

  • End‑to‑end project management 

  • KOL‑level scientific engagement 

Fast Contracting & Rapid Start-Up

  •  Streamlined templates 

  • Dedicated commercial and legal pathways 

  • Partner‑oriented processes 

FAQ

Still have questions?
Get in touch with us
 We operate strictly as an extension of your delivery capability — not as a competitor. Our teams integrate into your operational model, provide specialist expertise where needed, and maintain transparent communication throughout. This partnership approach is supported by our validated processes and audited quality systems that ensure trust and reliability. 

Owned and operated clinical sites give CROs predictable enrolment and reliable timelines. We guarantee bed capacity, accelerate site readiness, and remove dependency on third party availability, allowing CROs to confidently commit to sponsors without operational risk. 
 

 We maintain access to targeted earlyphase cohorts, including renally impaired and hepatically impaired volunteers. These specialist populations allow CROs to deliver more complex studies efficiently and without lengthy site feasibility delays. 

 Our CPU facilities cover the full spectrum of early clinical pharmacology, including:
• First-in-human (FIH)
• SAD/MAD and proof-of-concept

 PK/PD studies
• Drug–drug interactions
• Bioavailability/bioequivalence
• Pharmacogenetics (Renal & Hepatic Impairment)
• Biosimilars

 Yes. We can provide specific components (e.g., specialist populations, Clinical Pharmacology Unit delivery, challenge studies) or full end-to-end execution — depending on what the CRO needs to strengthen its proposal and delivery.